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T
he production of proteins by ge-
netically engineered Escherichia
coli bacteria cells has become
well established in biotechnol-
ogy research and large-scale production.
Cloning and expression of proteins in 
E. coli are favored in many instances be-
cause E. coli has relatively simple genetics, is
well characterized, and has a relatively rapid
growth rate. One disadvantage, however, of
expressing heterologous proteins in E. coli is
that the proteins are frequently expressed as
insoluble aggregated folding intermediates,
known as “inclusion bodies.” In order to re-
cover an active protein expressed in inclu-
sion bodies, the protein that is insoluble
must be solubilized with denaturants such
as 8 M urea or 6 M guanidine hydrochlo-
ride, and then the denaturant must be re-
moved under conditions that are optimal
for protein folding. While progress has been
made in the refolding of recombinant pro-
teins (1, 2), the specific folding conditions
regarding buffer composition, protein con-
centration, temperature, etc. must be opti-
mized for every protein. Even for refolding
processes that have been optimized, the
yield of renatured protein may still be rela-
tively low, requiring large volumes and sig-
nificant cost for the preparation of large
quantities of protein.
One approach to expressing heterolo-
gous proteins in soluble form has been to
co-express molecular chaperones which aid
in protein folding. Although there have
been several instances of E. coli chaperones
aiding the folding of heterologous proteins,
unfortunately it is a trial and error process
to determine the specific match between the
target protein and the chaperone that will
lead to correct folding (3, 4).
Another approach that has achieved suc-
cess in recent years in producing soluble
heterologous proteins in E. coli has been the
use of gene fusions. The first fusion protein
system specifically aimed at increasing solu-
bility of a target protein was the one in
which E. coli thioredoxin (TRX) was fused
to the N-terminus of the target protein (5).
Other carrier proteins that have been widely
used in fusion proteins in E. coli are maltose
binding protein (MBP) and glutathione S-
transferase (GST). MBP and GST were
chosen as carriers because they enable the
fusion protein to be affinity purified: MBP
binds to amylose, while GST binds to im-
mobilized glutathione. While these carrier
proteins have resulted in the successful over-
expression of many heterologous proteins in
E. coli, each was discovered empirically and
certainly may not possess maximal solubiliz-
ing characteristics. 
The new fusion protein systems that we
describe here are based on a systematic eval-
uation to identify E. coli proteins that have
the highest potential for solubility when
overexpressed. A modified version of the
solubility model of Wilkinson and Harrison
(6) for recombinant proteins expressed in E.
coli was used to determine the solubility po-
tential of the more than 4000 E. coli pro-
teins in the SwissProt protein database.
Based on this solubility model, we identi-
fied three E. coli proteins--BFR, GrpE, and
NusA--that gave a significantly higher level
of solubility when expressed as a fusion
with the target heterologous protein human
interleukin-3 (hIL-3) compared to the
fusion of TRX to hIL-3. NusA expressed as
a fusion with hIL-3 gave the highest level of
solubility and hIL-3 expression of the car-
rier proteins tested. NusA fused to human
interferon-γ  (hIFN-γ ), bovine growth hor-
mone (bGH), or tyrosinase from Rhizobium
meliloti was also expressed in nearly com-
pletely soluble form and at high levels. This
article elaborates on these new findings. 
Recombinant protein solubility
modeling
In the original model of Wilkinson and
Harrison (6) for the solubility of recombi-
nant proteins expressed in E. coli, five
amino acid-based parameters were corre-
lated with inclusion body formation. It has
since been discovered, however, that only
two of the parameters are critical in distin-
guishing soluble versus insoluble protein 
expression (7). The critical parameters are
the approximate charge average, which 
accounts for the differences in the numbers
of Asp plus Glu versus Lys plus Arg
residues, and the turn-forming residue con-
tent, which accounts for the total number
of  Asn,  Gly,  Pro,  and  Ser  residues.
Incorporation of the two-parameter solubil-
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Protein MW (kDa) Amino Acid Length Probability of
Solubility or Insolubility1
NusA 54.8 495 95% soluble
BFR 18.5 158 95% soluble
GrpE 21.7 197 92% soluble
thioredoxin 11.7 109 73% soluble
hIL-3 15.1 133 73% insoluble
bGH 21.6 189 60% insoluble
hIFN-γ 17.1 146 58% insoluble
tyrosinase 54.1 494 51% soluble
1. The revised Wilkinson-Harrison solubility model involves calculating a canonical variable (CV) or composite parameter for the protein for which the solubility is
being predicted. The canonical variable in the two-parameter model is defined as:
CV=λ 1(
N+G+P+S)
+λ 2|(
(R+K)–(D+E)
-0.03)|
nn
n  = number of amino acids in protein
N,G,P,S  = number of Asn, Gly, Pro, or Ser residues, respectively.
R,K,D,E = number of Arg, Lys, Asp, or Glu residues, respectively.
λ 1, λ 2 = coefficients (15.43 and -29.56, respectively)
The probability of the protein solubility is based on the parameter CV-CV', where CV' is the discriminant equal to 1.71. If CV-CV' is positive, the protein is predicted to 
be insoluble, while if CV-CV' is negative, the protein is predicted to be soluble.  The probability of solubility or insolubility can be predicted from the following equation:
Probability of solubility or insolubility = 0.4934 + 0.276 |(CV-CV')| - 0.0392 (CV-CV')2
Table 1. Predicted solubilities of carrier and target proteinsinNovations 11
ity model into a custom C computer pro-
gram allowed the rapid evaluation of all
known E. coli protein sequences. As input,
this program used a single text file created by
the SwissProt server (http://www.expasy.ch),
which contained approximately 4000 
E. coli protein sequences. 
E. coli proteins identified by the solubil-
ity model which possessed a solubility prob-
ability of greater than 90% were considered
for fusion protein experiments. The list of
possible carrier proteins was then reduced
to those which were stable when expressed
in E. coli as shown in previous studies.
Next, choices were further restricted to
those containing more than 100 amino
acids to ensure that predicted solubility
characteristics would not be simply limited
by the molecular weight of the carrier pro-
tein relative to the target protein chosen. 
Three E. coli proteins, NusA, BFR (bac-
terioferritin), and GrpE, were identified by
the solubility model as having a very high
probability (> 90%) of being soluble when
expressed in E. coli. All three of these pro-
teins were evaluated as N-terminal fusions
with human interleukin-3 (hIL-3), which
has been found in inclusion bodies both
when expressed alone (8) and as a fusion
protein with thioredoxin (5). Bovine
growth hormone (bGH) and human inter-
feron-γ (hIFN-γ ) were selected for fusion
with NusA at their N-terminus because
they had previously been expressed alone in
inclusion bodies (9, 10). Tyrosinase from
Rhizobium meliloti was not able to be over-
expressed by itself in E. coli but was ex-
pressed as a fusion protein with NusA 
connected to its N-terminus (11); this ty-
rosinase is interesting because of its large
molecular weight (54 kDa) and large
number of rare codons. The predicted solu-
bilities of the carrier and target proteins
studied, including the carrier thioredoxin as
a control, are shown in Table 1.
Evaluation of solubility of E. coli
fusion proteins
The results of overexpression of fusion
proteins in E. coli at 37°C are shown in
Figures 1, 2 and 3. The SDS-PAGE and
Western blot results show that all fusion
proteins containing hIL-3 were expressed at
a high level with respect to the percent of
the total cell protein, namely: NusA,
18.4%; GrpE, 7.4%; BFR, 13.7%; and
thioredoxin, 8.5% (see fig. 1). The highest
soluble expression level was achieved by the
NusA/hIL-3 protein (97% soluble), while
the thioredoxin/hIL-3 fusion protein was
expressed almost completely in the inclu-
sion body fraction (8% soluble). Thus, the
percentage solubility of the NusA/hIL-3
fusion protein was over 12 times that of the
thioredoxin/hIL-3 fusion protein. 
The Western blot (see fig. 1, lower
panel) shows, with more clarity, the distrib-
ution of hIL-3 among the soluble and insol-
uble fractions. BFR and GrpE are distrib-
uted between the soluble and insoluble
fractions. Upon centrifugation of BFR/hIL-
3 cultures at the end of induction periods, it
was noticed that the cell pellet had a slightly
red tint compared to uninduced cultures.
This is presumably due to the iron binding
properties of BFR (12) and serves as a con-
venient marker for confirmation of protein
expression. One striking finding from the
Western blot data (fig. 1) is that the level of
expression of hIL-3 in the soluble fraction
was higher in the NusA fusion than in the
other fusions. Thus, the large size of NusA
(55 kDa) was not at all limiting in being
able to express high levels of hIL-3.
In order to determine if the hIL-3 present
in each of the fusion proteins was biologi-
cally active, indicating that hIL-3 was prop-
erly folded, a cell proliferation assay was
performed on each fusion protein in soluble
cell lysate. hIL-3 activity was found to be
present in all fusion proteins, with 67% of
the hIL-3 determined to be active for the
NusA/hIL-3 fusion protein, which was the
highest of the fusion proteins tested (7). 
For the expression of the NusA/bGH
and NusA/hIFN-γ fusion proteins (see fig.
2), it is clear from SDS-PAGE and Western
blot results that the vast majority of these
fusion proteins are expressed in the soluble
fraction (estimated as 89% for NusA/bGH
and 87% for NusA/hIFN-γ ). To our knowl-
edge, this is the first evidence of soluble 
expression of bGH in E. coli. 
The fusion of NusA with the relatively
large tyrosinase (54 kDa) was expressed in
almost completely soluble form (>90%)
based on SDS-PAGE analysis (see fig. 3).
Thus, NusA may be a very good carrier pro-
tein for solubilizing large target proteins. In
Figure 1. Analysis of fusion proteins containing hIL-3
SDS-PAGE (upper panel) and Western blot (lower panel) analyses show NusA, GrpE, BFR, and thioredoxin fusion proteins containing hIL-
3. Equal portions of cell lysate, soluble fraction, and insoluble fraction were loaded. Fusion proteins were expressed from plasmid
pKK223-3 under control of the tac promoter in E. coli JM105 at 37°C. Cells were induced with 1 mM IPTG and grown for 3 h post-
induction. The Western blot was probed with mouse anti-hIL-3 monoclonal antibody and visualized using chemiluminescence. Percentage
solubility based on the blots (density of soluble band divided by the density of the soluble plus insoluble bands): 97%, NusA/hIL-3; 71%,
GrpE/hIL-3; 47% BFR/hIL-3; and 8% thioredoxin/hIL-3. u = uninduced whole cell lysate, i = induced whole cell lysate, sol = soluble 
fraction, ib = inclusion body fraction.
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a separate gene construction, we were not
able to express the tyrosinase gene by itself
at all (11); this is possibly due to the fact
that the tyrosinase gene has a high content
of rare codons (over three times as many as
in the gene for NusA), or because of a 5'-
mRNA structure that inhibits translation
initiation.
Because the levels of soluble hIL-3 
expression were the highest for the fusion
protein with NusA, despite the fact that
NusA was the largest of the carrier proteins
investigated, we postulated that the biologi-
cal activity of NusA might be a contributing
factor to solubilization. One of the biologi-
cal activities of NusA is that of pause-
enhancement during transcription (13). To
test whether NusA could independently in-
fluence the solubility of a target protein, we
co-expressed NusA and human interferon-γ
(hIFN-γ ), normally insoluble when ex-
pressed in E. coli by itself, using dicistronic
expression in E. coli. This strategy resulted
in an increase in hIFN-γ overexpression
(94% increase) when co-expressed with
NusA in a dicistronic system, compared to
when hIFN-γ was expressed by itself under
the control of the same promoter and ribo-
some binding site (11). However, no in-
crease in solubility was noted since hIFN-γ
appeared to be almost completely insoluble
either when expressed by itself or when co-
expressed with NusA. Therefore, the excel-
lent solubility of different proteins fused to
NusA does not appear to be due to the bio-
logical activity of NusA. 
Purification of hIL-3 expressed as a
NusA fusion 
Since the NusA/hIL-3 fusion protein 
exhibited the highest solubility and hIL-3
expression levels, we developed a purifica-
tion scheme for this system (7). A His6 tag
was added to the N-terminus of NusA for
purification by immobilized metal affinity
chromatography (IMAC) using an Ni2+
chelate affinity column. A factor Xa pro-
tease cleavage sequence (Ile-Glu-Gly-Arg)
connected NusA and hIL-3 in the original
construction. 
Following IMAC purification, the
His6NusA/hIL-3 fusion protein was di-
gested with factor Xa protease. The protease
digest was then passed over a Q Sepharose
anion exchange chromatography column to
remove hIL-3 from the digest mixture. Pure
hIL-3 was found to elute in the flow
through during loading of the Q Sepharose
column. The hIL-3 was purified to homo-
geneity after the anion exchange chro-
matography at a yield of 4.5 mg/L of 
expression culture (0.49 mg hIL-3 per gram
of cell paste) and a 13% recovery. The
largest loss of hIL-3 occurred in the IMAC
step, where the yield of hIL-3 was 32%.
This yield in the IMAC step is consistent
with the recovery results for the purification
by IMAC of an upstream stimulatory factor
(USF) with a His6 at the N terminus (14).
The percent recovery for the wild type and
mutant forms of USF were reported to be
17% and 28%, respectively, for the IMAC
step. The purified hIL-3 had full biological
activity when compared to an hIL-3 refer-
ence standard.
After the incubation of the NusA/hIL-3
fusion protein with factor Xa protease,
some non-specific cleavage of NusA was
noted (7). The use of a linker sequence be-
tween the C-terminus of NusA and the 
N-terminus of the factor Xa sequence
should increase specificity. It has previously
been shown that a glycine-rich linker (Pro-
Gly-Ile-Ser-Gly5) placed immediately
downstream of a thrombin cleavage site
greatly increased the cleavage efficiency of
several GST fusion proteins (15). Other
proteases could also be used, including en-
terokinase and Kex2, which both cut at the
C-terminus of their cleavage sequences
(Asp4-Lys and Leu-Phe-Lys-Arg, respec-
tively); neither of these cleavage sequences
are present in NusA.
Summary
This research has shown that selection of
proteins with high solubility based on a sta-
tistical solubility model of solubility in E.
coli has been a successful approach to ex-
pressing a target insoluble protein in soluble
form as part of a fusion protein. Three E.
coli proteins selected using this model-based
approach, NusA, GrpE, and BFR, all were
predicted to be more soluble than TRX
when expressed in E. coli, and fusions of all
three with hIL-3 had significantly higher
solubility than the fusion of TRX and hIL-
3. One of the carrier proteins studied,
NusA, may be advantageous in solubilizing
many target insoluble proteins, not only be-
cause of its good solubilizing characteristics,
but because of its very high expression level.
The good results of NusA in solubilizing a
54 kDa tyrosinase in a fusion protein may
Figure 2. Analysis of bovine growth hormone (bGH) and human interferon-γ (hIFN-γ ) 
expressed as fusions to NusA
Equal portions of cell lysate, soluble fraction, and insoluble fraction were analyzed by SDS-PAGE (upper panel) and Western blot (lower
panel). The NusA/bGH and NusA/hIFN-γ fusion proteins were expressed from plasmid pKK223-3 under control of the tac promoter in E.
coli JM105 at 37°C. Cells were induced with 1 mM IPTG and grown for 3 h post-induction. The Western blots were probed with rabbit
anti-bGH polyclonal antibody, murine anti-hIFN-γ monoclonal antibody, and visualized using chemiluminescence. Percentage solubility
based on blots: 89%, NusA/bGH; 87%, NusA/hIFN-γ . u = uninduced whole cell lysate, i = induced whole cell lysate, sol = soluble 
fraction, ib = inclusion body fraction.
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described in the accompanying article has
now been incorporated into the pET vector
system to create the pET43.1a-c(+) vector
series. These vectors contain the following
elements:
• Tightly controlled T7lac promoter and
optimal ribosome binding site
• N-terminal Nus•Tag™ fusion sequence
• Internal His•Tag® and S•Tag™ sequences
• Thrombin and enterokinase cleavage sites
• Multiple cloning sites in all reading frames
• Optional C-terminal HSV•Tag® and
His•Tag sequences
• bla (β -lactamase) and lacI (lac repressor)
genes oriented in the opposite direction
of the T7lac promoter
• ColE1 replication origin
Further enhancements in the generation
of soluble, properly folded target protein
may potentially be realized by combining
the Nus•Tag fusion technology with expres-
sion in Origami™ host strains. Origami
host strains are trxB/gor mutants (1) and are
permissive to the formation of disulfide
bonds in the cytoplasm. Therefore, target
proteins that require disulfide bond 
formation may benefit from expression in
these hosts. 
1. Aslund, F., Bessette, P., Georgiou, G.
and Beckwith, J. (1999) inNovations
10, 11–12.
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indicate that NusA may be a very good car-
rier for solubilizing large proteins. It was
possible to obtain fully active hIL-3 starting
from the NusA/hIL-3 fusion protein 
expressed in E. coli cells.  
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Figure 3. SDS-PAGE of R. meliloti tyrosinase expressed as a fusion to NusA
Equal portions of cell lysate, soluble fraction, and insoluble fraction were loaded and analyzed by SDS-PAGE. The NusA/tyrosinase fusion
protein was expressed from plasmid pKK223-3 under control of the tac promoter in E. coli JM105 at 37°C. Cells were 
induced with 1 mM IPTG and grown for 3 h post-induction.
Product Size Cat. No. Price
pET NusA Fusion System 43.1 70942-3 $310
(contains pET-43.1a, b, c(+) DNA, host strain glycerol stocks, and 
vector sequence CD)
pET NusA Fusion System 43.1
plus Competent Cells 70943-3 $373
(contains pET-43.1a, b, c(+) DNA, host strain glycerol stocks, host 
strain competent cells, and vector sequence CD)
pET-43.1a(+) DNA 10 µg 70939-3 $131
pET-43.1b(+) DNA 10 µg 70940-3 $131
pET-43.1c(+) DNA 10 µg 70941-3 $131
His•Bind® Purification Kit 70239-3 $142
(contains His•Bind Resin and buffers)
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NusA gene now available as a fusion tag in pET-43.1 series